Form 4: Phathom Pharmaceuticals Executive's Future Stock Vesting

Phathom Pharmaceuticals' Chief Legal Officer, Anne Marie Cook, reported the future vesting of performance stock units and subsequent sale of shares for tax withholding, scheduled for December 17, 2025.

Summary

• Anne Marie Cook, Chief Legal Officer & Corporate Secretary of Phathom Pharmaceuticals, Inc. (PHAT), filed a Form 4 reporting changes in beneficial ownership.
• On December 17, 2025, Cook is scheduled to acquire 17,370 shares of Common Stock at a price of $0, representing shares issued upon the vesting of performance stock units (PSUs).
• These PSUs were granted on June 23, 2025, with performance criteria determined to be satisfied on December 17, 2025.
• Concurrently, on December 17, 2025, Cook is scheduled to dispose of 7,703 shares of Common Stock at a price of $15.36 per share.
• These disposed shares are intended to satisfy the Issuer's tax withholding obligation related to the PSU vesting.
• Following these transactions, Cook's direct beneficial ownership of Common Stock will be 9,667 shares.

Sentiment

Score: 6

Explanation: The filing reports a routine, pre-scheduled executive compensation event (vesting of PSUs and tax-related share disposition). The vesting implies performance criteria are expected to be met, which is a positive, but the overall impact is neutral as it's a standard occurrence.

Positives

• The vesting of performance stock units indicates that the company's performance criteria, set for the grant, are expected to be met by December 17, 2025.

Negatives

• The disposition of 7,703 shares for tax withholding purposes reduces the executive's direct beneficial ownership, though this is a standard practice.

Future Outlook

This filing indicates a pre-scheduled future event related to executive compensation, specifically the vesting of performance stock units and associated tax-related share dispositions, expected to occur on December 17, 2025.

Industry Context

The vesting of performance stock units and subsequent sale of shares for tax withholding are standard components of executive compensation packages across various industries, designed to align management incentives with company performance and shareholder value.

Comparison to Industry Standards

• The structure of performance stock units (PSUs) tied to performance criteria is a common incentive mechanism in the pharmaceutical and biotechnology sectors, similar to practices at companies like Pfizer or Moderna.
• The disposition of shares to cover tax obligations upon vesting is a standard and expected practice for equity compensation, consistent with industry benchmarks.

Stakeholder Impact

• Shareholders: The transaction is a routine executive compensation event and is unlikely to have a significant direct impact on the company's stock price or fundamental value. It reflects the ongoing compensation structure for key management.

Key Dates

Recommendation

This Form 4 reports a future, routine vesting of performance stock units and subsequent sale of shares to cover tax obligations by a company executive. Such pre-scheduled transactions are common and generally do not indicate a change in the company's fundamental outlook or warrant a change in investment recommendation. The transaction itself does not provide new information that would alter the investment thesis for Phathom Pharmaceuticals.

Keywords

Phathom Pharmaceuticals, PHAT, Form 4, insider transaction, stock vesting, performance stock units, executive compensation, future transaction